Werewolf Therapeutics, Inc. — Form 10-Q
Filed July 31, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 78/100
What the filing says
On May 6, 2026, Werewolf Therapeutics sold substantially all assets of its 898 Program (an interferon-alpha therapeutic program) to Jazz Pharmaceuticals Ireland Limited for a non-refundable Closing Purchase Price of $21,000,000 USD. Assets transferred include patents, know-how, the transferred compound, regulatory documentation, and books/records; Jazz assumes specified liabilities. The original 2022 collaboration and license agreement between the parties terminates simultaneously. Additionally, on May 7, 2026, Werewolf terminated its lease for its Watertown, Massachusetts facility (originally expiring May 31, 2030) effective October 31, 2026 (or earlier with 30 days' notice after July 1), paying Jazz landlord $2,700,000 total settlement ($2,465,016 by May 15, 2026, plus $234,984 May rent already paid).
Why this rating
Sale of primary asset program for $21M (~53% of $39.6M market cap) is material; combined with facility exit signals strategic wind-down. Significant but company retains other programs (non-898) and IP; not immediate going-concern threat.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.